NCT01536379 - A Study of Belimumab in the Prevention of Kidney Transplant Rejection | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

September 30, 2013

Primary Completion Date

February 29, 2016

Study Completion Date

February 29, 2016

Conditions

Transplantation, Organ

Interventions

DRUG

Belimumab

Belimumab (10 mg/kg) will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)

DRUG

Placebo

Placebo will be given as an intravenous solution over a 1 hour time period administered every 4 weeks for 24 weeks (with an additional dose at Week 2)

Trial Locations (2)

CB2 0QQ

GSK Investigational Site, Cambridge

SE1 9RT

GSK Investigational Site, London